New sleeping pill may treat Alzheimer's

Share this article:

A new insomnia drug may be used for Alzheimer's and depression, according to its Japanese maker.

Takeda Pharmaceutical Co. Ltd., the Osaka-based drug manufacturer, could extend the use of Ramelteon -- a new sleeping pill to be released in the U.S. market in early fall -- to treat Alzheimer's disease and other illnesses. The new drug, which is in clinical trials in Japan and Europe, has a new mechanism that specifically targets the MT1 and MT2 receptors in the brain, which are critical in regulating the body's sleep-wake cycle.

The company filed for FDA approval for the drug last year and expects to gain approval with "non-scheduled drug" status, which means that no restrictions will be placed on how physicians prescribe the drug. It may start clinical development of the drug to treat Alzheimer's disease and depression after the pill's launch, the company announced.

Share this article:

More in News

CMS updates coding instructions for hospice site of service, principal diagnosis

CMS updates coding instructions for hospice site of ...

A new Medicare hospice manual update includes instructions for which principal diagnosis codes are acceptable, and clarifies which codes should be used for services in a skilled versus non-skilled nursing ...

Vast majority of nursing home residents chronically constipated, and it's not well ...

Chronic constipation is highly prevalent in nursing homes and not well controlled, leading to a high likelihood that residents develop fecal impaction, according to findings from a first-of-its kind study.

Federal judge dismisses nursing home 'kickback' case; upholds large X-ray company's 'swapping' ...

The way mobile x-ray company Mobilex bills nursing homes is acceptable, a federal judge recently determined. Mobilex is the nation's largest provider of mobile diagnostic services. It had been facing whistleblower charges that it effectively paid kickbacks to nursing homes through an arrangement known as ...